Tianlong is the foundation of the market as the pilot, the research and development of the production and research technology, and pursues the innovative drive-type high-tech enterprise of independent brands. Since its establishment in 1997, the company has consistently adhering to the public, market-oriented, customer-centric development concept, is committed to research and development, production and sales of instruments and in vitro diagnostic reagents in the field of genetic testing, molecular diagnosis.
One of the innovative leaders in domestic genetic testing, molecular diagnosis, Tianlong in order to better serve medical diagnosis, biological testing, individualized medical, food safety and inspection and quarantine, life science, medical research and medical training, etc.It has now been developed to have a company group with a number of subsidiaries such as Tianlong, Suzhou Tianlong, Wuxi Ruiqi.In vitro diagnostic products + third-party medical inspection service + hospital investment full chain medical health industrial integrated service provider. Tianlong has obtained the world's 500-bit SK multinational enterprise group in 2012, 2018 received Shanghai Juhua Biological Engineering Co., Ltd., 2018.Stock code: 002022Strategic investment. In the future, Tianlong and Baohua will launch in-depth cooperation in the product line, channels, markets and after-sales services in the field of molecular diagnosis, and achieve strategic complementation and jointly build world-class molecular diagnosis enterprises.
Tianlong has PCR technology, gene chip technology, sequencing technologyWaiting for several major technical platforms, based on the prior art platform, the development, production and sales of various products are implemented.More than 50 medical equipment CFDA registration certificates, 5 CE certifications, 5 national key new product certificates, passed ISO9001 and 13485 quality system assessmentTianlong products are currently covered from nano-magnetic bead nucleic acid extractors, real-time fluorescent quantitative PCR instruments and other molecular testing equipment to large automated nucleic acid detection workstations, supporting reagents, reaching hundreds, service infectious diseases, genetic diseases, tumors and precision Medical test diagnosis has become an independent research and development and production enterprise in the domestic nucleic acid molecule diagnosis of products. Tianlong is also a national high-tech enterprise, the national intellectual property pilot enterprise, the National Development and Reform Commission Biomedical Engineering High Technology Industrialization Demonstration Enterprise, Shaanxi Province and Xi'an Innovative Enterprise, Shaanxi Provincial Life Science Testing Instrument Engineering Technology Research Center Relying on the unit, Holds the lead for the national major scientific equipment development project, the national 863 program, the national science and technology support plan, and the provincial and municipal major scientific research and industrialization projects, while the participation of the development and implementation of multiple projects.
Tianlong products have made important contributions in hepatitis, AIDS, hand, foot and mouth disease, avian influenza, eugenics, food safety testing, and sudden public health incidents have been widely concerned by leaders at all levels. In 2009, Tianlong Fluorescent Quantitative PCR instrument inspected the first case of H1N1 in Shaanxi; 2012 Handheld ATP fluorescent detector thousands of Chinese standard food safety departments; 2013 people infected H7N9 avian influenza prevention and control period, Tianlong fluorescent Quantitative PCR and nucleic acid extractors and reagents are equipped with a number of provincial and land-level CDCs, hospitals such as Zhejiang University, Hubei, Jiangsu, Beijing, etc., and completed thousands of suspected flu samples. Viral nucleic acid extraction and screening, CCTV News Network and the official website of the Ministry of Science and Technology conducted special reports; 2013 fluorescent quantitative PCR instruments were broughturs in large quantities of medical and CDC systems in multiple provinces.Tianlong products apply for more than 20 intellectual property rights such as invention patents, and obtain six provincial and ministerial level science and technology awards. The results are selected in \"National Eleventh Five-Year Major Science and Technology Achievement Exhibition \", \"Twelfth Five-Year Technology Innovation Achievement Exhibition \" Deputy Prime Minister Liu Yandong, Wan Steel Minister, Deputy Minister of Hou Jianguo, etc.In 2014, the West Afbola epidemic, Tianlong Technology utilizes inventive patents such as hypersensitive molecular diagnosis and other inventions, and rapid response to the development and production of Ebola virus nucleic acid detection reagents. The kit passes through the CFDA strict assessment, adopted emergency approval and won national CFDA registration certificates, officially included in my country and West Africa to diagnose Ebola virus and epidemic prevention and control emergency response products. In June 2015, South Korea broke the MRS Syndrome (MERS), Tianlong Technology took the lead in developing successful MERS testing reagents and exported to South Korea, sent to many provincial CDCs and hospitals in China, used for national flu monitoring network, fixed hospital The initial screening of influenza, fever patients, etc. In June 2016, Liu Yandong, member of the Political Bureau of the Central Committee and Vice Premier of the State Council, in Jiangsu survived national innovation, driving development strategy and people's livelihood reform, company founders, and national science and technology innovation entrepreneurial talents Peng Jiancai talents conducted product function demonstration, and reported work. In 2017, Tianlong Fluorescence Quantitative PCR instrument and reagent detected the first case of H7N9 people in Shaanxi. We have a dream of creating healthy life with science and technology, helping my country's public health epidemic prevention and control!
Tianlong Technology has always put talent strategy in the first, adhering to the concept of \"ability, attitude and quality, education and qualifications and light \", building a leading industry development, industry management leadership, industry management , The research, marketing and management team with powerful operational power and other aspects.
As the market development needs and the company's products are constantly rich, the company has established clinical division, life sciences, overseas business, managed and regional co-construction project, tumor individualized medication project department, etc., through distribution Many flexible cooperation models such as businesses, direct sales, products are now spread all over the country, export overseas, provide high-quality products and services for global users.
Tianlong will continue to pay attention to customer needs, respond quickly, and serve medical diagnosis, scientific research, biological testing, individualized medical, independent laboratory, food safety and inspection and quarantine. In the face of future opportunities and challenges, Tianlong will work together with all walks of cooperation, to establish a national brand as Tianlong mission, create first-class molecular diagnosis products, and continue to work hard for human health.
The new Tianlong will continue to use the responsibility and feelings of corporate citizens, adhering to the spirit of excellence, self-improvement, honor, and act, and make unremitting efforts to build Tianlong build a nationally renowned enterprise in the field of molecular diagnosis!
Tianlong Technology is based on market-oriented, and has been based on the research and development of science and technology, and pursues independent brands.